Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data

A ‘global’ model of hERG K+ channel was built to satisfy three basic criteria for QSAR models in drug discovery: (1) assessment of the applicability domain, (2) assuring that model decisions can be interpreted by medicinal chemists and (3) assessment of model performance after the model was built. A combination of D-optimal onion design and hierarchical partial least squares modelling was applied to construct a global model of hERG blockade in order to maximize the applicability domain of the model and to enhance its interpretability. Additionally, easily interpretable hERG specific fragment-based descriptors were developed. Model performance was monitored, throughout a time period of 15 months, after model implementation. It was found that after this time duration a greater proportion of molecules were outside the model’s applicability domain and that these compounds had a markedly higher average prediction error than those from molecules within the model’s applicability domain. The model’s predictive performance deteriorated within 4 months after building, illustrating the necessity of regular updating of global models within a drug discovery environment.

[1]  P. Carrupt,et al.  Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .

[2]  Antranig Basman,et al.  HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. , 2004, Progress in biophysics and molecular biology.

[3]  J. Valentin,et al.  Nonclinical proarrhythmia models: predicting Torsades de Pointes. , 2005, Journal of pharmacological and toxicological methods.

[4]  T. Nishikawa,et al.  A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[5]  Pierre Bruneau,et al.  Search for Predictive Generic Model of Aqueous Solubility Using Bayesian Neural Nets , 2001, J. Chem. Inf. Comput. Sci..

[6]  John Sharkey,et al.  Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.

[7]  A. Bass,et al.  Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. , 2005, Journal of pharmacological and toxicological methods.

[8]  M Pastor,et al.  VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  Brian B. Goldman,et al.  A model for identifying HERG K+ channel blockers. , 2004, Bioorganic & medicinal chemistry.

[10]  J. Li,et al.  A two-state homology model of the hERG K+ channel: application to ligand binding. , 2005, Bioorganic & medicinal chemistry letters.

[11]  Gabriele Cruciani,et al.  Predictive models for hERG potassium channel blockers. , 2005, Bioorganic & medicinal chemistry letters.

[12]  Derek J Trezise,et al.  IonWorks™ HT: A New High-Throughput Electrophysiology Measurement Platform , 2003, Journal of biomolecular screening.

[13]  Rober t C. Glen A fast empirical method for the calculation of molecular polarizability , 1994, J. Comput. Aided Mol. Des..

[14]  Erik Johansson,et al.  Megavariate analysis of hierarchical QSAR data , 2002, J. Comput. Aided Mol. Des..

[15]  A. Brown,et al.  Drugs, hERG and sudden death. , 2004, Cell calcium.

[16]  F. Österberg,et al.  Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods , 2005, FEBS letters.

[17]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[18]  S. Wold Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .

[19]  A. Cavalli,et al.  QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development , 2005, Medicinal research reviews.

[20]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[21]  Alex M Aronov,et al.  Predictive in silico modeling for hERG channel blockers. , 2005, Drug discovery today.

[22]  Matthew Clark,et al.  Development and Evaluation of an in Silico Model for hERG Binding , 2006, J. Chem. Inf. Model..

[23]  Glenn J. Myatt,et al.  LeadScope: Software for Exploring Large Sets of Screening Data , 2000, J. Chem. Inf. Comput. Sci..

[24]  Douglas M. Hawkins,et al.  Assessing Model Fit by Cross-Validation , 2003, J. Chem. Inf. Comput. Sci..

[25]  G. Keserü Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.

[26]  Michael C Sanguinetti,et al.  Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.

[27]  B. Small,et al.  Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. , 2006, Journal of pharmacological and toxicological methods.

[28]  Roy J. Vaz,et al.  Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.

[29]  T G Hammond,et al.  Use of in vitro methods to predict QT prolongation. , 2005, Toxicology and applied pharmacology.

[30]  J. Hancox,et al.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 , 2003, British journal of pharmacology.

[31]  Michael Markert,et al.  Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. , 2004, Journal of pharmacological and toxicological methods.

[32]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[33]  Gisbert Schneider,et al.  A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries , 2002, Chembiochem : a European journal of chemical biology.

[34]  R. Rasmusson,et al.  Functionally-distinct proton-binding in HERG suggests the presence of two binding sites , 2007, Cell Biochemistry and Biophysics.

[35]  R Purdy,et al.  A mechanism-mediated model for carcinogenicity: model content and prediction of the outcome of rodent carcinogenicity bioassays currently being conducted on 25 organic chemicals. , 1996, Environmental health perspectives.

[36]  Bernd Beck,et al.  Onion design and its application to a pharmaceutical QSAR problem , 2004 .

[37]  S C Basak,et al.  Predicting acute toxicity (LC50) of benzene derivatives using theoretical molecular descriptors: a hierarchical QSAR approach. , 1997, SAR and QSAR in environmental research.

[38]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.